Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...

head-to-head comparative trial’s two-year outcomes of the Evolut transfemoral transcatheter aortic valve replacement (TAVR) ...

Medtronic plc MDT recently unveiled two-year Small Annuli Randomized to Evolut or SAPIEN (“SMART”) Trial results at the Cardiovascular Research Technologies (“CRT”) 2025 conference in Washington, D.C.

Medtronic released positive two-year trial Evolut TAVR results that demonstrated superior valve performance in small aortic ...

"The two-year results highlight the continued superior performance of the Evolut TAVR valve in these patients. While we would not yet expect to see a significant difference in the composite ...

Medtronic (MDT) released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN, SMART, Trial, the largest international ...

The two-year results highlighted the continued superior performance of the Evolut TAVR valve in patients with a small aortic annulus. These results will be followed to assess long-term outcomes.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMa ...